Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sangamo Therapeutics Inc chart...

About the Company

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

CEO

Alexander Macrae

Exchange

NASDAQ

Website

https://www.sangamo.com/

$565M

Total Revenue

520

Employees

$119M

Market Capitalization

-0.43

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SGMO News

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

3d ago, source:

One thing we could say about the analysts on Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - they aren't optimistic, having just ...

4 Analysts Assess Sangamo Therapeutics: What You Need To Know

15d ago, source:

In the latest quarter, 4 analysts provided ratings for Sangamo Therapeutics (NASDAQ:SGMO), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, ...

Sangamo Prices Direct Offering

6d ago, source:

Belite Retreats on Start of Clinical Trial <li /> KB Flat on Opening Chino Contour Site <li /> Generational Gap on Clean ...

Sangamo Therapeutics Inc SGMO

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sangamo Therapeutics (NASDAQ: SGMO)

6d ago, source: The Motley Fool

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited ...

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

7d ago, source: Morningstar

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the ...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

15d ago, source: Business Wire

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results ...

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

16d ago, source: Business Wire

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV ...

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

9d ago, source:

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, ...

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

7d ago, source: Nasdaq

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with ...

Sangamo Therapeutics, Inc. (SGMO)

7d ago, source: Yahoo Finance

One thing we could say about the analysts on Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) - they aren't optimistic... RICHMOND, Calif., March 22, 2024--SANGAMO THERAPEUTICS ANNOUNCES PRICING OF $24. ...

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

7d ago, source: Stockhouse

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...